Radiation Oncology/RTOG Trials/9910
< Radiation Oncology < RTOG Trials
|
RTOG 99-10 (PROSTATE)
- Title: A Phase III Trial to Evaluate The Duration of Neoadjuvant Total Androgen Suppression (TAS) and Radiation Therapy (RT) in Intermediate Risk Prostate Cancer
- Objective: To compare the efficacy of moderate-duration (28-week) neoadjuvant total androgen suppression and RT with short-duration (8-week) neoadjuvant total androgen suppression and RT as related to disease-specific survival.
- Protocol:
- Arm 1: TAS x 8 weeks followed by 70.2 Gy RT + concurrent TAS
- Arm 2: TAS x 28 weeks followed by 70.2 Gy RT + concurrent TAS
- Eligibility:
- (cT1b-T4 and GS 2-6 and PSA 10-100) or
- (cT1b-T4 and GS 7 and PSA <20) or
- (T1b-T1c and GS 8-10 and PSA <20)
- N0M0
- Enrollment Target: 1540 patients
- Activation: February 14, 2000
- Closed: May 3, 2004
This article is issued from Wikibooks. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.